Date: Monday, June 3, 2019
Session Name: Poster Session C: Kidney: Cardiovascular and Metabolic
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall C & D
*Purpose: To assess the efficacy and safety of febuxostat in the treatment of hyperuricemia in renal transplant recipients.
*Methods: A total number of 124 renal transplant patients with hyperuricemia who were prescribed febuxostat between June 2016 and July 2018 were retrospectively analyzed. The initial dose of febuxostat was 10-40 mg/d depending on serum uric acid level and body weight. The uric acid (UA), liver function and renal function parameters before and 3 months after febuxostat treatment was compared. Adverse events and patient and renal allograft survival were recorded throughout the follow-up period.
*Results: Serum uric acid was significantly decreased after three months of febuxostat treatment from 501.21 ± 71.7 μmol/L to 374.7 ± 94.5 μmol/L (Table 1, p<0.001). 82 out of 124 patients (66.1%) reached to normal UA level at month 3 after febuxostat treatment. Estimated glomerular filtration rate (eGFR) was maintained (54.4 ± 15.4 vs 55.8 ± 16.2 mL/min/1.73m2, p =0.074). No severe adverse event was observed. All patients and renal grafts survived during the follow-up period.
|Before treatment||3 months after treatment||P-value|
|Serum uric acid(μmol/L)||501.21 ± 71.7||374.7 ± 94.5||<0.001|
|Serum creatinine(μmol/L)||127.7 ± 36.9||126.7 ± 39.8||0.063|
|eGFR(ml/min/1.73m2)||54.4 ± 15.4||55.8 ± 16.2||0.074|
|WBC(109/L)||8.0 ± 2.6||7.3 ± 2.3||<0.05|
|Hb(g/L)||121.6 ± 19.8||131.6 ± 17.6||<0.001|
*Conclusions: Febuxostat is effective and safe in the treatment of hyperuricemia in renal transplant recipients.
To cite this abstract in AMA style:Liu L, Jiang J, Fu Q, Long S, Zhang H, Su X, Li J, Wu C, Deng R, Zhang W, Wang C. Efficacy And Safety Of Febuxostat In Renal Transplant Recipients With Hyperuricemia [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/efficacy-and-safety-of-febuxostat-in-renal-transplant-recipients-with-hyperuricemia/. Accessed December 4, 2020.
« Back to 2019 American Transplant Congress